1. Chazova I.E. i soavt. Lechenie dislipidemii u bol'nykh arterial'noi gipertoniei. Terapevticheskii arkhiv, 2007; 79; №4, s.53-57.
2. Balantyne C. et al. Lipids and CVD managemetowards a global consensus. Eur Heart J, 2005; 26: 2224-2231.
3. Kannel W. Hypertension as a risk for cardiac events: epidemiologic results of long-term studies. J of Cardiovasc Pharmac 1993; 21 (suppl. 2); S20S13: S27-S37.
4. Sans S., Kesteloor H., Kromhout D. on behalf of the Task Force. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231-1248.
5. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20536 high-risk individuals; a randomized placebo-controlled trial. The Lancet 2002; Vol. 360: 7-22.
6. Boitsov S.A. Sosudy kak platsdarm i mishen' arterial'noi gipertonii. Consilium Medicum, 2006; №3: s.2-9.
7. Nedogoda S.V. i soavt. Atorvastatin i uluchshenie elastichnosti sosudov pri arterial'noi gipertonii. Consilium Medicum, 2007; №1: s.12-15.
8. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981-2997.
9. Sever PS, Dahlof B, Poulter NR et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-1158.
10. Strazzullo P.,et al. Do statins reduce blood pressure? A meta-analisys of randomized, controlled trials. Hypertension, 2007; 49: 792-798.
11. Leonova Yu.L. Problema nepatentovannykh preparatov. RMZh 2001, t.9, №12, s.524-526.
12. Petrov V.I., Nedogoda S.V., Sabanov A.V. Farmakoekonomicheskie aspekty primeneniya statinov pri kratkosrochnoi gipolipidemicheskoi terapii. Kachestvennaya klinicheskaya praktika 2003; 1: 46-51.
13. Podkolozina M.V., Nemchenko A.S. Farmakoekonomicheskii analiz: problemy dostupnosti serdechno-sosudistykh lekarstvennykh sredstv. Provizor 2000, №6, s.20-22.
14. Mnushko Z, Grekova I, Khizhnyak T i dr. Izuchenie potrebitel'skikh i vrachebnykh predpochtenii pri vybore khimioterapevticheskikh preparatov. Provizor 2000, №1, s.12-15.
15. Lyutov N.G. Dzheneriki na farmatsevticheskom rynke Rossii. RMZh 2001, t.9, №24, s.1118-19.
16. Lazebnik L.B., Kadiskaya M.I. Sravnenie farmakoekonomicheskoi effektivnosti statinov i fibratov pri vtorichnoi profilaktike ishemicheskoi bolezni serdtsa u zhenshchin. Problemy standartizatsii v zdravookhranenii, 2000; №4, s. 102.
17. Nurmukhametov R. Sravnenie simvastatina i atorvastatina: ekonomicheskii analiz. RMZh 2000; t.8; №13-14: s.580-584.
18. Mancia G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
Email this article 